ATE427967T1 - Spezifische antikírperfragmente fur das humane carcinoembryonic antigen (cea) - Google Patents

Spezifische antikírperfragmente fur das humane carcinoembryonic antigen (cea)

Info

Publication number
ATE427967T1
ATE427967T1 AT03720119T AT03720119T ATE427967T1 AT E427967 T1 ATE427967 T1 AT E427967T1 AT 03720119 T AT03720119 T AT 03720119T AT 03720119 T AT03720119 T AT 03720119T AT E427967 T1 ATE427967 T1 AT E427967T1
Authority
AT
Austria
Prior art keywords
antibodial
cea
fragments
specific
carcinoembryonic antigen
Prior art date
Application number
AT03720119T
Other languages
English (en)
Inventor
Cowley Jorge Victor Gavilondo
Avila Marta Ayala
Almeida Freya De Los Milagros Freyre
Castro Boris E Acevedo
Garcia Hanssel Bell
Navarro Lourdes Tatiana Roque
Lopez Luis Javier Gonzalez
Alvarez Jose Alberto Cremata
Segui Raquel Montesino
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of ATE427967T1 publication Critical patent/ATE427967T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03720119T 2002-04-29 2003-04-28 Spezifische antikírperfragmente fur das humane carcinoembryonic antigen (cea) ATE427967T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20020086A CU23228A1 (en) 2002-04-29 2002-04-29 FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME

Publications (1)

Publication Number Publication Date
ATE427967T1 true ATE427967T1 (de) 2009-04-15

Family

ID=40293094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03720119T ATE427967T1 (de) 2002-04-29 2003-04-28 Spezifische antikírperfragmente fur das humane carcinoembryonic antigen (cea)

Country Status (17)

Country Link
US (2) US20050158322A1 (de)
EP (1) EP1505076B1 (de)
JP (1) JP2006500913A (de)
KR (1) KR100700323B1 (de)
CN (1) CN1326877C (de)
AR (1) AR039454A1 (de)
AT (1) ATE427967T1 (de)
AU (1) AU2003223831A1 (de)
BR (1) BR0304649A (de)
CA (1) CA2482411A1 (de)
CU (1) CU23228A1 (de)
DE (1) DE60327072D1 (de)
ES (1) ES2325492T3 (de)
MX (1) MXPA04010695A (de)
RU (1) RU2294939C2 (de)
WO (1) WO2003093315A2 (de)
ZA (1) ZA200408720B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110001A2 (es) * 2006-03-29 2007-10-04 Centro De Ingenieria Genetica Y Biotecnologia Moléculas quiméricas fusionadas a matrilina 1, de uso terapéutico.
CA2652703C (en) 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
HUE026846T2 (en) 2007-12-18 2016-08-29 Bioalliance Cv Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
KR20180077322A (ko) * 2009-04-30 2018-07-06 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들
RU2412251C1 (ru) * 2009-06-15 2011-02-20 Юрий Леонидович Дорохов Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении
RU2395234C1 (ru) * 2009-07-24 2010-07-27 Учреждение Российской Академии Наук Институт Молекулярной Биологии Им. В.А. Энгельгардта Ран (Имб Ран) ОПРЕДЕЛЕНИЕ СНИЖЕНИЯ УРОВНЯ мРНК ГЕНА ZG16 КАК СПОСОБ ДИАГНОСТИКИ РАКА ТОЛСТОЙ КИШКИ И НАБОР ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US10550196B2 (en) 2014-04-27 2020-02-04 Famewave Ltd. Humanized antibodies against CEACAM1
CN104628859A (zh) * 2015-01-26 2015-05-20 佳德资本投资管理（Bvi）有限公司 抗人癌胚抗原抗体及其编码基因和应用
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
CN111533805B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高亲和力纳米抗体及其应用
CN112409485B (zh) * 2020-10-21 2022-10-25 北京纽安博生物技术有限公司 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen

Also Published As

Publication number Publication date
ZA200408720B (en) 2006-03-29
KR20050007376A (ko) 2005-01-17
CA2482411A1 (en) 2003-11-13
MXPA04010695A (es) 2005-02-17
CN1649901A (zh) 2005-08-03
US20050158322A1 (en) 2005-07-21
CN1326877C (zh) 2007-07-18
CU23228A1 (en) 2007-09-26
ES2325492T3 (es) 2009-09-07
AU2003223831A1 (en) 2003-11-17
US20070199078A1 (en) 2007-08-23
EP1505076A2 (de) 2005-02-09
RU2294939C2 (ru) 2007-03-10
EP1505076B1 (de) 2009-04-08
WO2003093315A3 (es) 2004-01-08
AR039454A1 (es) 2005-02-23
JP2006500913A (ja) 2006-01-12
BR0304649A (pt) 2004-07-20
RU2004134601A (ru) 2005-07-10
DE60327072D1 (de) 2009-05-20
KR100700323B1 (ko) 2007-03-29
WO2003093315A2 (es) 2003-11-13

Similar Documents

Publication Publication Date Title
IS7499A (is) Mennsk mótefni gegn beta-amýloíðpeptíðum
IS7670A (is) Samsett meðferð fyrir offjölgunar sjúkdóma
ATE427967T1 (de) Spezifische antikírperfragmente fur das humane carcinoembryonic antigen (cea)
EP1554982A4 (de) Ultraschallgerät
NO20054078D0 (no) Humane antistoffer spesifikke for Interleukin 15 (IL15).
DE60239766D1 (de) Wärmebehandlungssystem
NO20052149D0 (no) Vaksine.
ATE322850T1 (de) Schminkgerät
DE112004000860D2 (de) Gating-Verfahren, Gating-Gerät, sowie Therapieeinrichtung
FR2835731B1 (fr) Appareil de mammographie
ITBO20020259A0 (it) Dispositivo di arricciatura
DE60334272D1 (de) Heizgerät
DE602004012607D1 (de) Homokinetisches kreuzgelenk
DE60317825D1 (de) Tomographischies bildgebungsverfahren
DE50310160D1 (de) Heizeinrichtung
DE50305053D1 (de) Epilationsgerät
ITTO20020477A0 (it) Dispositivo per elettroporazione.
EP1571112A4 (de) Aufzugsvorrichtung
ITBO20020235A0 (it) Dispositivo di prelievo dello sfrido
NO20042850L (no) Kreftbehandling
DE10240912B4 (de) Strahlentherapiegerät
FR2845885B1 (fr) Appareil de micro-abrasion
ITRM20030283A1 (it) Mezzi terapeutici e diagnostici per i papillomi.
AU2003267162A8 (en) Cancer associated antigens, sga-56m and sga-56mv, and uses thereof
FI20021281A7 (fi) Mammografialaite

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1505076

Country of ref document: EP

REN Ceased due to non-payment of the annual fee